Drug Trial Radar · NCT00405067
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: Mar 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 2006
Primary completion
Jan 2007
Study completion Jan 2007
Sponsor
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 29, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of this study are to evaluate the efficacy and safety of combination therapy BMS-201038 (AEGR-733) plus ezetimibe vs. each agent given alone on LDL cholesterol and other lipoproteins over 12 weeks of therapy.
Conditions
- Hypercholesterolemia
Interventions
BMS-201038 (AEGR-733)Drug
EzetimibeDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between TreatmentsTime frame: Baseline and 12 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmanet, Inc
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.